Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2025)

Indivior Pharmaceuticals' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $3.0 million for Q1 2025.

• On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $3.0 million in Q1 2025; TTM through Mar 2025 was $3.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $11.0 million, down 72.5% from the prior year.
• Other Accumulated Expenses slipped to $3.0 million in Q1 2025 per INDV's latest filing, from $11.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $40.0 million in Q4 2023 and bottomed at $3.0 million in Q1 2025.
• The 3-year median for Other Accumulated Expenses is $11.0 million (2024), against an average of $18.0 million.
• Biggest YoY gain for Other Accumulated Expenses was 72.5% in 2024; the steepest drop was 72.5% in 2024.
• Year by year, Other Accumulated Expenses stood at $40.0 million in 2023, then tumbled by 72.5% to $11.0 million in 2024, then sank by 72.73% to $3.0 million in 2025.
• Per Business Quant, the three latest INDV Other Accumulated Expenses figures stand at $3.0 million (Q1 2025), $11.0 million (Q4 2024), and $40.0 million (Q4 2023).